Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Cross-sectional Study on Intradialytic Hypertension at Four Haemodialysis Units in the Western Cape

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01916668
Recruitment Status : Completed
First Posted : August 5, 2013
Last Update Posted : May 7, 2014
Sponsor:
Information provided by (Responsible Party):
Mogamat-Yazied Chothia, University of Stellenbosch

Brief Summary:
Observational evidence indicates that intradialytic hypertension is associated with high morbidity & mortality. The investigators impression is that this problem may be more prevalent than initially suspected. To the investigators knowledge, there are no studies on intradialytic hypertension in the South African haemodialysis population.

Condition or disease
Intradialytic Hypertension

Detailed Description:

Introduction

Intradialytic hypertension (IDH) is the paradoxical rise in blood pressure (BP) during or immediately after haemodialysis.

Nephrologists have yet to arrive at a standard definition of IDH. Definitions vary widely from systolic blood pressure rises of ≥ 10mmHg, rise in mean arterial pressure (MAP) during dialysis > 15mmHg to hypertension that appears resistant to ultrafiltration during or immediately after dialysis.1 Depending on the definition used, the prevalence of IDH varies between 5-15%.

This phenomenon may appear trivial to the inexperienced doctor. However, IDH increases the risk of hospitalization and death as reported in the Crit-Line Intradialytic Monitoring Benefit Study (CLIMB) and United States Renal Data System (USRDS) haemodialysis study.

The pathogenesis of IDH is unclear. A number of factors have been implicated and probably work synergistically to promote the rise in BP. These include: subclinical volume overload, activation of the sympathetic and renin-angiotensin-aldosterone systems, endothelial dysfunction, sodium gain during dialysis, use of erythropoietin stimulating agents (ESAs) and removal of anti-hypertensive agents during dialysis.

The management of IDH relies heavily on control of sodium and fluid dynamics. There are no randomized controlled studies to guide management.

Objectives

Primary: Determine the prevalence of IDH at four haemodialysis units in the Western Cape

Secondary: To examine the association between IDH and the following potential risk factors:

Intradialytic weight gain, the presence and/or degree of fluid overload as assessed by bioimpedance monitoring, quantity and timing of anti-hypertensive drugs, ESA dose and route of administration, time-averaged sodium concentration, dialysate calcium concentrations and haemodialysis modality.

Methods

Study Design

A multicentre, cross-sectional study on chronic haemodialysis patients at four adult dialysis units in the Western Cape will be conducted.IDH will be defined as a rise of ≥10mmHg in systolic blood pressure between pre- and post-dialysis in at least 4 out of six dialysis sessions. Patients screened as eligible for inclusion in the study will be identified from haemodialysis charts by the primary investigator (PI). They will then be approached by the PI, who will try to obtain informed consent. Once informed consent has been obtained and no exclusion criteria are present, the patient will be enrolled. A study ID number will be allocated.

Using a standard operating protocol (SOP), weight, BP, pulse rate, bioimpedance, ultrafiltration rates and volumes will be determined before, hourly during dialysis and 30 minutes after completion of dialysis. Timing and use of antihypertensive drugs, ESA use, dialysis modality, intradialytic calcium and time averaged sodium levels will be determined. All data extracted will be captured onto a standardised data sheet.

Layout table for study information
Study Type : Observational
Actual Enrollment : 200 participants
Observational Model: Case-Control
Time Perspective: Cross-Sectional
Official Title: A Cross-sectional Study on Intradialytic Hypertension at Four Haemodialysis Units in the Western Cape, South Africa
Study Start Date : April 2013
Actual Primary Completion Date : April 2014
Actual Study Completion Date : May 2014

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Dialysis




Primary Outcome Measures :
  1. Prevalence of intradialytic hypertension at four haemodialysis units in the Western Cape [ Time Frame: Up to 1 year ]

Secondary Outcome Measures :
  1. Participants pre- and post hemodialysis bioimpedance measurements [ Time Frame: Up to 1 year ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Chronic haemodialysis patients
Criteria

Inclusion Criteria:

  • Males and females age > 18 years
  • Ability to give informed consent

Exclusion Criteria:

  • Inability to take blood pressure by routine methods in the upper limbs
  • Inability to give informed consent
  • Contraindications to bioimpedance monitoring (pre-existing implanted cardiac devices such as pacemakers, cardioverter defibrillators; amputees)
  • Intercurrent acute illness

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01916668


Locations
Layout table for location information
South Africa
Tygerberg Academic Hospital
Cape Town, Western Cape, South Africa, 7505
Sponsors and Collaborators
University of Stellenbosch
Investigators
Layout table for investigator information
Principal Investigator: Mogamat-Yazied Dr Chothia, FCP(SA) University of Stellenbosch
Layout table for additonal information
Responsible Party: Mogamat-Yazied Chothia, Consultant Nephrologist, University of Stellenbosch
ClinicalTrials.gov Identifier: NCT01916668    
Other Study ID Numbers: S12/10/264
First Posted: August 5, 2013    Key Record Dates
Last Update Posted: May 7, 2014
Last Verified: May 2014
Additional relevant MeSH terms:
Layout table for MeSH terms
Hypertension
Vascular Diseases
Cardiovascular Diseases